Alger, Jeffry R.
https://orcid.org/0000-0003-1699-089X
Mayo Clinic
University of California, Los Angeles
Citations 2
Relationship between hippocampal atrophy and neuropathology markers: A 7T MRI validation study of the EADC‐ADNI Harmonized Hippocampal Segmentation Protocol
Apostolova, Liana G. , Zarow, Chris, Biado, Kristina, Hurtz, Sona, Boccardi, Marina , Honarpisheh, Hedieh, Blanken, Anna E., Brook, Jenny , Tung, Spencer, Kraft, Emily, Lo, D.C.W. , Ng, Denise , Alger, Jeffry R. , Vinters, Harry V. , Bocchetta, Martina , Duvernoy, Henri M., Jack, Clifford R. , Frisoni, Giovanni B. , Segmentation, EADC‐ADNI Working Group on the Harmonized Protocol for Manual Hippocampal, Bartzokis, George, Csernansky, John G., deToledo‐Morrell, Leyla, Lehéricy, Stéphane , Malykhin, Nikolai , Pantel, Johannes, Pruessner, Jens C. , Watson, Craig, Boccardi, Marina , Frisoni, Giovanni B. , Somme, Johanne Hatteland , Segmentation, EADC‐ADNI Working Group on the Harmonized Protocol for Manual Hippocampal, Leon, Mony J. de , Killiany, Ronald , Soininen, Hilkka S. , Jack, Clifford R , Bocchetta, Martina
Alzheimer's & Dementia | January 22, 2015 | Volume: 11 | Issue: 2 | Pages: 139-150
AbstractObjectiveThe pathologic validation of European Alzheimer's Disease Consortium Alzheimer’s Disease Neuroimaging Initiative Center Harmonized Hippocampal Segmentation Protocol (HarP).MethodsTemporal lobes of nine Alzheimer's disease (AD) and seven cognitively normal subjects were scanned post‐mortem at 7 Tesla. Hippocampal volumes were obtained with HarP. Six‐micrometer‐thick hippocampal slices were stained for amyloid beta (Aβ), tau, and cresyl violet. Hippocampal subfields were manually traced. Neuronal counts, Aβ, and tau burden for each hippocampal subfield were obtained.ResultsWe found significant correlations between hippocampal volume and Braak and Braak staging (ρ = −0.75, P = .001), tau (ρ = −0.53, P = .034), Aβ burden (ρ = −0.61, P = .012), and neuronal count (ρ = 0.77, P < .001). Exploratory subfield‐wise significant associations were found for Aβ in Cornu Ammonis (CA)1 (ρ = −0.58, P = .019) and subiculum (ρ = −0.75, P = .001), tau in CA2 (ρ = −0.59, P = .016), and CA3 (ρ = −0.5, P = .047), and neuronal count in CA1 (ρ = 0.55, P = .028), CA3 (ρ = 0.65, P = .006), and CA4 (ρ = 0.76, P = .001).ConclusionsThe observed associations provide pathological confirmation of hippocampal morphometry as a valid biomarker for AD and pathologic validation of HarP.
Acute Stroke Imaging Research Roadmap
Wintermark, Max , Alexandrov, Andrei V. , Alger, Jeffry R. , Bammer, Roland , Baron, Jean‐Claude , Derdeyn, Colin P. , Donnan, Geoffrey A. , Eastwood, James D., Fiebach, Jochen B. , Fisher, Marc , Furie, Karen L. , Goldmakher, Gregory V., Hacke, Werner, Kidwell, Chelsea S., Kloska, Stephan P. , Köhrmann, Martin , Lee, Ting‐Yim , Lev, Michael H. , Liebeskind, David S. , Østergaard, Leif , Provenzale, James, Schellinger, Peter D. , Sorensen, A. Gregory , Wardlaw, Joanna M. , Wu, Ona , Warach, Steven , Albers, Gregory W. , Davis, Stephen M. , Demaerschalk, Bart M. , Koroshetz, Walter J. , Lees, Kennedy R. , Liebeskind, David S. , Powers, William J. , Silbergleit, Robert , Wardlaw, Joanna Marguerite , Wintermark, Max , Wu, Ona , Derdeyn, Colin P
Stroke | April 10, 2008 | Volume: 39 | Issue: 5 | Pages: 1621-1628
The recent “Advanced Neuroimaging for Acute Stroke Treatment” meeting on September 7 and 8, 2007 in Washington DC, brought together stroke neurologists, neuroradiologists, emergency physicians, neuroimaging research scientists, members of the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), industry representatives, and members of the US Food and Drug Administration (FDA) to discuss the role of advanced neuroimaging in acute stroke treatment. The goals of the meeting were to assess state-of-the-art practice in terms of acute stroke imaging research and to propose specific recommendations regarding: (1) the standardization of perfusion and penumbral imaging techniques, (2) the validation of the accuracy and clinical utility of imaging markers of the ischemic penumbra, (3) the validation of imaging biomarkers relevant to clinical outcomes, and (4) the creation of a central repository to achieve these goals. The present article summarizes these recommendations and examines practical steps to achieve them.